




Mark Berlin (Autor)

## Predicting Oral Absorption of Poorly Soluble Weakly Basic Drugs

Mark Berlin

### Predicting Oral Absorption of Poorly Soluble Weakly Basic Drugs



Cuvillier Verlag Göttingen  
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/7128>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany  
Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>



# Index

|          |  |           |
|----------|--|-----------|
| <b>1</b> | <b>Introduction .....</b>  | <b>1</b>  |
| 1.1      | Drug transit through the upper GI tract.....   | 2         |
| 1.2      | Determinants of drug absorption .....  | 4         |
| 1.2.1    | The biopharmaceutics classification system .....   | 4         |
| 1.2.2    | The biopharmaceutics drug disposition classification system.....   | 5         |
| 1.2.3    | The developability classification system .....   | 6         |
| 1.3      | Weak bases and the GI tract.....   | 7         |
| 1.3.1    | pH in the GI tract .....   | 7         |
| 1.3.2    | Bile salts and food in the GI tract .....  | 9         |
| 1.3.3    | Gastric emptying .....   | 10        |
| 1.4      | Simulation of <i>in vivo</i> drug dissolution .....  | 10        |
| 1.4.1    | Dissolution media simulating GI fluids .....   | 10        |
| 1.4.2    | Simulation of GI dissolution conditions .....  | 11        |
| 1.5      | Drug permeability assessment .....   | 14        |
| 1.6      | Physiologically based pharmacokinetic modeling .....   | 16        |
| 1.6.1    | PBPK modeling approaches .....   | 16        |
| 1.6.2    | Software for PBPK modeling.....  | 17        |
| 1.6.2.1  | <i>MATLAB<sup>®</sup> and STELLA<sup>®</sup></i> .....   | 17        |
| 1.6.2.2  | <i>Commercial software (Simcyp<sup>®</sup>, GastroPlus<sup>®</sup>, PK-Sim<sup>®</sup>) and GI-Sim<sup>®</sup></i> ..... | 18        |
| 1.7      | Aims of this work .....  | 20        |
| <b>2</b> | <b>Materials and Methods.....</b>  | <b>21</b> |
| 2.1      | Materials.....   | 21        |
| 2.1.1    | Chemicals .....  | 21        |
| 2.1.2    | Model substance cinnarizine.....   | 22        |
| 2.1.3    | Model substance atazanavir .....   | 24        |
| 2.2      | Methods.....   | 28        |
| 2.2.1    | HPLC-UV setup.....   | 28        |
| 2.2.2    | Biorelevant media .....  | 29        |
| 2.2.3    | Solubility assessment.....   | 31        |
| 2.2.4    | Dissolution experiments .....  | 33        |
| 2.2.5    | “Dumping” experiments.....   | 33        |
| 2.2.6    | Transfer experiments .....   | 33        |
| 2.2.7    | WinNonLin <sup>®</sup> - assessment of pharmacokinetics of API formulations .....  | 38        |
| 2.2.8    | STELLA <sup>®</sup> .....  | 39        |
| 2.2.9    | Simcyp <sup>®</sup> .....  | 47        |
| 2.2.10   | Statistical comparison of predicted plasma profiles using different transfer experiment approaches .....                 | 51        |



|          |   |            |
|----------|---|------------|
| <b>3</b> | <b>Results</b> .....  | <b>52</b>  |
| 3.1      | Cinnarizine – investigation of <i>in vitro</i> behavior .....   | 52         |
| 3.1.1    | Solubility results .....  | 52         |
| 3.1.2    | Dissolution of cinnarizine tablets in biorelevant media.....  | 53         |
| 3.1.3    | Dumping of pure cinnarizine .....   | 57         |
| 3.1.4    | Investigation of supersaturation and precipitation of cinnarizine during transfer experiments.                                  | 58         |
| 3.2      | Cinnarizine - <i>in silico</i> plasma profile simulation.....   | 66         |
| 3.2.1    | Evaluation of distribution and elimination kinetics of various cinnarizine tablets using WinNonLin® .....                       | 66         |
| 3.2.2    | STELLA® model - investigation of permeability restrictions of cinnarizine using fed state simulations .....                     | 67         |
| 3.2.3    | STELLA® “dissolution-only” vs. “supersaturation and precipitation” PBPK model in cinnarizine fasted state simulations.....      | 69         |
| 3.2.4    | STELLA® statistical comparison analysis of different transfer rates .....   | 73         |
| 3.2.5    | STELLA® sensitivity analysis of cinnarizine plasma profile predictions .....  | 74         |
| 3.2.6    | Summary of cinnarizine plasma profile simulations using Simcyp® .....   | 77         |
| 3.3      | Summary of the cinnarizine investigation and formulation suggestions.....   | 78         |
| 3.4      | Atazanavir sulfate – investigation of <i>in vitro</i> behavior .....  | 80         |
| 3.4.1    | Solubility results .....  | 80         |
| 3.4.1.1  | <i>Equilibrium solubility</i> .....   | 80         |
| 3.4.1.2  | <i>Kinetic solubility</i> .....   | 82         |
| 3.4.2    | Dissolution results of atazanavir sulfate capsules in biorelevant media .....   | 83         |
| 3.4.3    | Dumping results of atazanavir sulfate .....   | 87         |
| 3.4.4    | Investigation of the atazanavir sulfate concentration profile during simulated transfer from the stomach to the intestine ..... | 88         |
| 3.5      | Atazanavir sulfate - <i>in silico</i> plasma profile simulation .....   | 95         |
| 3.5.1    | Evaluation of distribution and elimination kinetics of atazanavir using WinNonLin® analysis of literature PK data .....         | 95         |
| 3.5.2    | Permeability evaluation of atazanavir .....   | 96         |
| 3.5.3    | STELLA® plasma profile predictions of atazanavir capsules in the fasted state .....   | 97         |
| 3.5.4    | STELLA® sensitivity analysis on atazanavir plasma profile predictions .....   | 104        |
| 3.6      | Summary of atazanavir plasma profile simulations using Simcyp® .....  | 109        |
| 3.7      | Summary of the atazanavir investigation and formulation suggestions .....   | 110        |
| <b>4</b> | <b>General discussion and conclusions</b> .....   | <b>113</b> |
| 4.1      | Choosing the right <i>in vitro</i> investigation approach.....  | 113        |
| 4.2      | Formulation enhancement approaches for weakly basic drugs .....   | 120        |
| 4.3      | Choosing the right PBPK modeling approach .....   | 122        |
| 4.3.1    | Development and evolution of the STELLA® model.....   | 122        |



|           |  |            |
|-----------|--|------------|
| 4.3.2     | Self-built versus commercial PBPK models (STELLA <sup>®</sup> versus Simcyp <sup>®</sup> ) ..... | 123        |
| 4.3.2.1   | <i>Input of release and dissolution profiles</i> .....   | 124        |
| 4.3.2.2   | <i>Opportunities for simulating pharmacokinetics of modified release formulations</i> .....      | 125        |
| 4.3.2.3   | <i>Input of permeability</i> .....   | 125        |
| 4.3.2.4   | <i>Middle-out and Bottom-up modeling approaches</i> .....  | 126        |
| 4.3.2.5   | <i>Virtual populations</i> .....   | 127        |
| 4.3.2.6   | <i>Summary</i> .....   | 127        |
| 4.4       | Outlook .....  | 128        |
| <b>5</b>  | <b>Summary</b> .....   | <b>131</b> |
| <b>6</b>  | <b>German Summary (Deutsche Zusammenfassung)</b> .....   | <b>137</b> |
| <b>7</b>  | <b>Appendix</b> .....  | <b>143</b> |
| 7.1       | STELLA <sup>®</sup> sensitivity analysis of cinnarizine plasma profile predictions.....          | 143        |
| 7.2       | STELLA <sup>®</sup> sensitivity analysis of atazanavir sulfate plasma profile predictions.....   | 145        |
| 7.3       | Simcyp <sup>®</sup> plasma profile predictions of cinnarizine .....                              | 148        |
| 7.3.1     | Simcyp <sup>®</sup> plasma profile predictions of cinnarizine in the fasted state .....          | 148        |
| 7.3.2     | Simcyp <sup>®</sup> plasma profile predictions of cinnarizine in the fed state .....             | 155        |
| 7.3.3     | Simcyp <sup>®</sup> sensitivity analysis of cinnarizine plasma profile predictions .....         | 161        |
| 7.3.4     | Simcyp <sup>®</sup> plasma profile predictions of cinnarizine using fitted Vd.....               | 172        |
| 7.4       | Simcyp <sup>®</sup> plasma profile predictions of atazanavir .....                               | 176        |
| 7.4.1     | Simcyp <sup>®</sup> plasma profile predictions of atazanavir in the fasted state.....            | 176        |
| 7.4.2     | Simcyp <sup>®</sup> plasma profile predictions of atazanavir in the fed state.....               | 184        |
| 7.4.3     | Simcyp <sup>®</sup> sensitivity analysis of atazanavir plasma profile predictions.....           | 188        |
| <b>8</b>  | <b>References</b> .....  | <b>203</b> |
| <b>9</b>  | <b>Curriculum Vitae</b> .....  | <b>216</b> |
| 9.1       | Personal Information .....   | 216        |
| 9.2       | Professional experience .....  | 216        |
| 9.3       | Education .....  | 217        |
| <b>10</b> | <b>Scientific Publications</b> .....   | <b>218</b> |
| 10.1      | Papers .....   | 218        |
| 10.2      | Posters .....  | 218        |
| <b>11</b> | <b>Academic Teachers</b> .....   | <b>218</b> |